Keywords: Body: Urogenital, Contrast mechanisms: Molecular imaging
Prostate-specific membrane antigen-targeted positron emission tomography (PSMA PET) has made a significant impact on management of patients with prostate cancer. Compared to conventional cross-sectional imaging, PSMA PET provides superior sensitivity for tumor detection in the setting of biochemical recurrence as well as for detection of metastatic disease in those with high-risk disease. PSMA PET is also used to determine eligibility for treatment with radioligand PSMA-directed therapy, which has been demonstrated to improve survival. We will review the added value of PSMA PET in management of patients with prostate cancer and its synergistic role with MRI in this setting.